In the group with a CPS of at least 1, the median survival was not significantly altered (17.6 vs.
16 months;P= .1125).Grade 3 to 5 treatment-related adverse events occurred in 68.1% of patients in the pembrolizumab group and 66.9% of patients in the placebo group.
Two deaths occurred in the pembrolizumab group (acute kidney injury and pneumonia).
There were no deaths in the placebo group.
Grade 3 to 4 immune-mediated adverse events occurred in 5.3% of patients in the pembrolizumab group, none of which led to death.
At the second interim analysis, the median follow-up was 25.9 months in the pembrolizumab-and-chemotherapy group and 26.3 months in the placebo-and-chemotherapy group.